Literature DB >> 18637054

Evaluation of the prognostic powers of various tumor status grading scales in patients with hepatocellular carcinoma.

Yeon Seok Seo1, Young Jin Kim, Soon Ho Um, Hanna Yoo, Jae Won Lee, Yong Sik Kim, Yoon Tae Jeen, Hoon Jai Chun, Chang Duck Kim, Ho Sang Ryu.   

Abstract

BACKGROUNDS AND AIM: Several tumor status grading scales are available for patients with hepatocellular carcinoma (HCC), which include several tumor-node-metastasis (TNM) systems and clinical staging systems, such as Cancer of the Liver Italian Program (CLIP) and Barcelona Clinic Liver Cancer (BCLC). This study was performed to analyze the prognostic powers of these tumor status grading systems in HCC.
METHODS: A retrospective cohort of 499 consecutive patients with HCC was included. The tumor statuses of all patients were classified according to several TNM systems (sixth version of the American Joint Committee on Cancer, fourth version of the Liver Cancer Study Group of Japan [LCSGJ], and the United Network for Organ Sharing UNOS system) and according to the tumor status grading scales of the BCLC (TBCLC) and CLIP (TCLIP) systems. Prognostic powers were quantified using a linear trend chi(2)-test, c-index, and the likelihood ratio (LHR) chi(2)-test, and correlated using Cox's regression model adjusted using the Akaike information criterion (AIC).
RESULTS: Of the TNM systems, the fourth LCSGJ system had the highest prognostic power (LHR chi(2) = 7.20, AIC = 4803.02). However, when TBCLC and TCLIP were included in the analysis, TCLIP showed the best predictive power (LHR chi(2) = 29.52, AIC = 4799.82).
CONCLUSION: TCLIP had best predictive power in HCC patients of the various tumor staging systems examined. To improve prognostic power, factors other than tumor burden, such as tumor behavior, should be included in the tumor status grading system for HCC.

Entities:  

Mesh:

Year:  2008        PMID: 18637054     DOI: 10.1111/j.1440-1746.2008.05480.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  3 in total

Review 1.  Current management of hepatocellular carcinoma: an Eastern perspective.

Authors:  Hyung Joon Yim; Sang Jun Suh; Soon Ho Um
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

2.  Research reporting standards for radioembolization of hepatic malignancies.

Authors:  Riad Salem; Robert J Lewandowski; Vanessa L Gates; Charles W Nutting; Ravi Murthy; Steven C Rose; Michael C Soulen; Jean-Francois H Geschwind; Laura Kulik; Yun Hwan Kim; Carlo Spreafico; Marco Maccauro; Lourens Bester; Daniel B Brown; Robert K W Ryu; Daniel Y Sze; William S Rilling; Kent T Sato; Bruno Sangro; Jose Ignacio Bilbao; Tobias F Jakobs; Samer Ezziddin; Suyash Kulkarni; Aniruddha Kulkarni; David M Liu; David Valenti; Philip Hilgard; Gerald Antoch; Stefan P Muller; Hamad Alsuhaibani; Mary F Mulcahy; Marta Burrel; Maria Isabel Real; Stewart Spies; Abdulredha A Esmail; Jean-Luc Raoul; Etienne Garin; Mathew S Johnson; Al B Benson; Ricky A Sharma; Harpreet Wasan; Bieke Lambert; Khairuddin Memon; Andrew S Kennedy; Ahsun Riaz
Journal:  J Vasc Interv Radiol       Date:  2011-03       Impact factor: 3.464

3.  Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems.

Authors:  Chang Liu; Li-gen Duan; Wu-sheng Lu; Lu-nan Yan; Guang-qin Xiao; Li Jiang; Jian Yang; Jia-yin Yang
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.